A tricontinental view of IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 18, Issue 8, 2003, Pages 1541-1548

  Geddes, Colin C ^a   Rauta, Virpi ^b   Gronhagen Riska, Carola ^b   Bartosik, Lukasz P ^c   Jardine, Alan G ^d   Ibels, Lloyd S ^e   Pei, York ^e   Cattran, Daniel C ^e  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e St Andrews and Wesley Hospitals   (Australia)

Author keywords

Chronic renal failure; Geographical variation; IgA nephropathy; Lead time bias; Natural history; Progression

Indexed keywords

CREATININE; PROTEIN;

ADULT; ARTICLE; AUSTRALIA; CANADA; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE CLEARANCE; DATA ANALYSIS; DETERIORATION; DIET; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FINLAND; GENETICS; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPOTHESIS; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED KINGDOM; URINARY EXCRETION;

AUSTRALIA; BLOOD PRESSURE; CREATININE; DISEASE PROGRESSION; FINLAND; GLOMERULONEPHRITIS, IGA; HUMANS; LINEAR MODELS; ONTARIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SCOTLAND; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042665524     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg207     Document Type: Article

References (22)

1. Berger J. IgA glomerular deposits in renal disease. Transplant Proc 1969; 1: 939-944
2. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988; 12: 340-347
3. D'Amico G. Natural history of IgA nephropathy: role of clinical and histological prognostic markers. Am J Kid Dis 2000; 36: 227-237
4. Nolin L, Courteau M. Management of IgA nephropathy: evidence based recommendations. Kidney Int 1999; 55: 56
5. Korevaar JC, Jansen MAM, Dekker FW et al. for the Netherlands Cooperative Study on the Adequacy of Dialysis Study Group. When to initiate dialysis: effect of proposed US guidelines on survival. Lancet 2001; 358: 1046-1050
6. Geddes CC, Fox JG, Allison ME, Boulton-Jones JM , Simpson K. An artificial neural network can select patients at high risk of developing progressive IgA nephropathy more accurately than experienced nephrologists. Nephrol Dial Transplant 1998; 13: 67-71
7. Harden PN, Geddes C, Rowe PA et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-1542
8. Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function. A model for estimating risk of progression in mild disease. Clin Nephrol 2002; 58: 85-94
9. Ibels LS, Gyory AZ, Caterson RJ et al. Recognition and management of IgA nephropathy. Drugs 1998; 55: 73-83
10. Ibels LS, Gyory AZ, Caterson RJ et al. Primary IgA nephropathy. Natural history and factors of importance in the progression of renal impairment. Kidney Int 1997; 52 Int: S67-S70
11. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 1994; 73: 79-102
12. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735
13. Cockcroft DW, Gault MH: Prediction of creatinine clearance from the serum creatinine. Nephron 1976; 16: 31-41
14. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Int Med 1993; 118: 201-210
15. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919
16. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. 'Gruppo Italiano di Studi Epidemiologici in Nefrologia' (GISEN). Kidney Int 1998; 53: 1209-1216
17. Fellin G, Gentile MG, Duca G, D'Amico G. Renal function in IgA nephropathy with established renal failure. Nephrol Dial Transplant 1998; 3: 17-23
18. Rennke H, Anderson S, Brenner BM. Structural and functional correlations in the progression of renal disease. In: Tisher C, Brenner B, eds. Renal Pathology. Lippincott, Philadelphia, PA: 1989: 43-66
19. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997; 100: 814-820
20. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC: The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10: 1772-1777
21. Orth SR, Stockmann A, Conradt C et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926-931
22. Radford MG Jr, Donadio JV Jr, Bergstralh EJ. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207